ProMIS Neurosciences (PMN) Free Cash Flow (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Free Cash Flow came in at -$12.4 million in Q1 2026, down 151.35% YoY from $24.1 million in Q1 2025, and down 33.42% on a QoQ basis from -$9.3 million in Q4 2025.
ProMIS Neurosciences (PMN) Free Cash Flow (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Free Cash Flow data on file, last reported at -$12.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 151.35% year-over-year to -$12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.6 million (down 63.06% YoY) and the FY2025 annual result came in at -$28.1 million, down 3.45% from the prior year.
- Free Cash Flow fell to -$12.4 million in Q1 2026, from -$9.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q2 2024 to a low of -$12.4 million in Q1 2026.
- A 5-year average of -$5.6 million and a median of -$4.6 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 301.75% — and 2025, when it surged 52.13%.
- Tracing PMN's Free Cash Flow over 5 years: stood at -$4.6 million in 2022, then gained by 17.47% to -$3.8 million in 2023, then slumped by 131.89% to -$8.7 million in 2024, then decreased by 6.5% to -$9.3 million in 2025, then tumbled by 33.42% to -$12.4 million in 2026.
- The last three Free Cash Flow figures came in at -$12.4 million (Q1 2026), -$9.3 million (Q4 2025), and -$10.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | -10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.40 Mn |
| Jun 30, 2026 | -10.40 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Dec 31, 2024 | -8.72 Mn |
| Dec 31, 2024 | -8.72 Mn |
| Sep 30, 2024 | -6.67 Mn |
| Sep 30, 2024 | -6.67 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -10.29 Mn |
| Mar 31, 2024 | -10.29 Mn |